Jounce Therapeutics Inc

Jounce Therapeutics — Investor Presentation (September 2019)

22 slides from Jounce Therapeutics's investor presentation, Sep 4, 2019

  1. Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company

    Exhibit 99.1 Jounce Therapeutics A Next Gen Immunotherapy Company

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for Jounce’s product candidates and any futu

  3. Slide 3: Investment Highlights and Differentiation

    Investment Highlights and Differentiation Vopratelimab: ICOS Agonist in Phase 2 • Clinical benefit associated with a mechanistic biomarker • Phase 2 EMERGE study underway, designed on translational data • Opportunity for differentiation – harnessing CD4 T cells to benefit cancer patients Translation

  4. Slide 4: The Jounce Translational Science Platform

    The Jounce Translational Science Platform Discovery Engine Clinical Programs Translational Drug Discovery Reverse Translational Analysis • Sustainable engine • MOA / responders vs. non-responders • 3 development programs in 6 years • Patients more likely to respond 4 | Jounce Therapeutics © Septembe

  5. Slide 5: Jounce Immunotherapy Pipeline

    Jounce Immunotherapy Pipeline Preclinical Clinical Program Target Biology Discovery IND Enabling Phase 1 Phase 2 Phase 3 Development Programs CD4 T cell Vopratelimab ICOS focused NSCLC and Bladder Cancer CD8 T cell JTX-4014 PD-1 focused Suppressive JTX-8064 LILRB2 macrophage Discovery Programs Not D

  6. Slide 6: Development Programs

    Development Programs Vopratelimab JTX-4014 JTX-8064

  7. Slide 7: Vopratelimab: Value Proposition

    Vopratelimab: Value Proposition • Clinical Data – ORR, PFS, OS tied to emergence of ICOS hi CD4 T effector cells in patients – ICOS hi CD4 T cells emerge due to vopratelimab not PD-1 – Safe and well tolerated, no T cell depletion in humans • Antibody characteristics – Selectively activates ICOS rece

  8. Slide 8: Differentiated Approach: Why Activated CD4 T Cells Matter

    Differentiated Approach: Why Activated CD4 T Cells Matter Moving Beyond PD-1 Centric Approach CD4 T Cell Opportunity for Vopratelimab • Orchestrates a coordinated immune response • CD4 T cells currently under exploited for therapeutic benefit • Required for optimal CD8 T cell activity • Vopra expand

  9. Slide 9: Vopratelimab Mechanism of Action from Clinical and Pre-clinical Studies

    Vopratelimab Mechanism of Action from Clinical and Pre-clinical Studies 1st Signal 2nd Signal Potential Clinical Benefit Activation of ICOS lo to ICOS hi Co-Stimulation of ICOS hi ICOS ICOS Vopratelimab Vopratelimab • Cancer Antigen Priming • Scientifically Rational Combos (example + anti-CTLA-4) Re

  10. Slide 10: Clinical Benefit Correlates with Vopratelimab Mechanistic Biomarker

    Clinical Benefit Correlates with Vopratelimab Mechanistic Biomarker Vopratelimab Causes Emergence of ICOS hi CD4 T Cells in ICOS hi CD4 T Cells Emerge in Patients with Blood of Responding Patients; PD-1i Do Not Target Lesion Reductions* Background: ICONIC Trial Phase 1/2 Study of Vopratelimab +/- Ni

  11. Slide 11: ICONIC Trial Efficacy: ICOS hi vs. ICOS lo CD4 T Cells

    Clinical Benefit Correlates with Vopratelimab Mechanistic Biomarker ICONIC Trial Efficacy: Relationship to ICOS hi vs. ICOS lo CD4 T Cells* ICOS hi (n=18) ICOS lo (n=32) RECIST 1.1 ORR 4 (22.2%) 0 Median PFS 6.2 months 2 months Median OS 21.4 months 9 months Progression Free Survival Overall Surviva

  12. Slide 12: ICOS hi CD4 T Cells Persist Throughout Durable Response

    ICOS hi CD4 T Cells Persist Throughout Durable Response Tumor Reduction Data cut-off 19-AUG-2019 • Late stage patients with no available therapy – TNBC and 3 gastric cancer – 3 of 4 responders are now target lesion CRs* % Change Change % LesionTarget in Days on Treatment • ICOS hi CD4 T cells ICOS h

  13. Slide 13: Clinical and Translational Data Drive New Opportunities for Vopratelimab

    Clinical and Translational Data Drive New Opportunities for Vopratelimab ICOS hi CD4 T Cells associated with improvements in ORR, PFS, OS* Maximize ICOS hi CD4 T Cells Prior to Vopratelimab Combination Vopratelimab Agents that induce ICOS hi CD4 T cells Induce or Detect ICOS hi ICOS hi CD4 T Cells

  14. Slide 14: Vopratelimab Phase 2 EMERGE Study

    Vopratelimab Phase 2 EMERGE Study Induction of ICOS hi by Ipilimumab Followed by Vopratelimab Enrollment Commenced June 2019 Ipilimumab Vopratelimab Ipilimumab and Vopratelimab Combination • Mechanism is independent of PD-1 • PD-1 experienced patients are a growing unmet need CTLA-4i Induce ICOS hi

  15. Slide 15: Development Programs

    Development Programs Vopratelimab JTX-4014 JTX-8064

  16. Slide 16: JTX-4014: PD-1 Inhibitor On Track

    JTX-4014: PD-1 Inhibitor On Track • Safety and efficacy data in 2H19 • Established safety and RP2D • Completed Phase 1 enrollment • IND filed Sept 2018 Well-characterized PD-1 antibody Objective: Monotherapy safety & POC • Fully human IgG4 • For use in combinations with potential • Blocks binding to

  17. Slide 17: Development Programs

    Development Programs Vopratelimab JTX-4014 JTX-8064

  18. Slide 18: JTX-8064: Further Showcases Jounce's Translational Science Platform

    JTX-8064: Further Showcases Jounce’s Strength of Translational Science Platform Target • JTX-8064: LILRB2 inhibitor • Novel antibody from the Jounce Translational Science Platform • Highly selectively monoclonal antibody that reprograms human macrophages to an anti-tumor phenotype License Terms • Ex

  19. Slide 19: The Jounce Approach: Sustainable Discovery

    The Jounce Approach: Sustainable Discovery Translational Science Innovative & Sustainable Discovery Pipeline Platform Immuno-suppressive T regulatory cells Inhibit immune suppressive activity Stromal cells Approach for cold tumors that lack T cells New target ID from 1000s of human tumors Immuno-sup

  20. Slide 20: 2019 Milestones

    2019 Milestones . Three immunotherapies in the clinic  Two wholly owned immunotherapies in the clinic  Exclusively licensed JTX-8064  Vopratelimab: Data update including PFS and OS from ICONIC at AACR  Vopratelimab: Initiate new Phase 2 studies  JTX-4014: Establish safety and RP2D . Advance nex

  21. Slide 21: Financial Strength and Flexibility

    Financial Strength and Flexibility • Jounce Therapeutics (NASDAQ: JNCE) Company History • Strong balance sheet: – $152M cash and investments, Event Date Gross $ Comment as of June 30, 2019 Series A 2013 $47M Third Rock Ventures • Updated Financial guidance: Series B 2015 $56M Fidelity, – 2019 gross

  22. Slide 22: Jounce Therapeutics: A Next Gen Immunotherapy Company

    Jounce Therapeutics A Next Gen Immunotherapy Company

Jounce Therapeutics — Investor Presentation (September 2019) on 6ix